Results 221 to 230 of about 2,675,009 (295)

Patient-reported outcome measurements in clinical trials in Saudi Arabia: A cross-sectional analysis of ClinicalTrials.gov. [PDF]

Saudi Med J
Al-Aqeel SA, AlKofide HA.
europepmc   +1 more source

PIN27 PROSPECTIVE OBSERVATIONAL STUDY OF PATIENT REPORTED OUTCOMES FORAZITHROMYCIN VS. USUAL CARE IN THE TREATMENT OF ACUTE BACTERIAL EXACERBATIONS OF CHRONIC BRONCHITIS

, 2005
AP Milstone, Irene D. Feurer, John D. Harriett, DR Luke   +3 more
openalex   +1 more source

The influence of ROS1 fusion partners and resistance mechanisms in ROS1‐TKI‐treated non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga, Christa Dijkhuizen, Patrick Korthuis, Wim Timens, Harry Groen, Jeroen Hiltermann, Anke van den Berg, Lyndsay Drayer, Anthonie van der Wekken   +8 more
wiley   +1 more source

Quality of patient-reported outcome measures for acute bronchitis: a systematic review of instruments and measurement properties. [PDF]

J Patient Rep Outcomes
Donhauser T, Piontek K, Baalmann AK, Apfelbacher C.   +3 more
europepmc   +1 more source

PED4 SUSTAINED IMPROVEMENT IN PATIENT-REPORTED OUTCOMES (PRO) AND NORMALIZATION OF HEALTHCARE UTILIZATION (HCU) DURING GROWTH HORMONE (GH) REPLACEMENT THERAPY IN HYPOPITUITARY ADULTS IN THE NETHERLANDS

, 2005
Maria Kołtowska‐Häggström, J. Dorrestijn, Marjolein Pompen, HC Monteban, A Mattsson, H. Koppeschaar   +5 more
openalex   +1 more source

YAP1::TFE3 mediates endothelial‐to‐mesenchymal plasticity in epithelioid hemangioendothelioma

Molecular Oncology, EarlyView.
The YAP1::TFE3 fusion protein drives endothelial‐to‐mesenchymal transition (EndMT) plasticity, resulting in the loss of endothelial characteristics and gain of mesenchymal‐like properties, including resistance to anoikis, increased migratory capacity, and loss of contact growth inhibition in endothelial cells.
Ant Murphy, Samuel Hartzler, Paula A. Vargas Carranza, Shyaman Jayasundara, Madison E. Yates, Nimod D. Janson, Bozhi Liu, Annaleigh Benton, Majid Kazemian, Jason A. Hanna   +9 more
wiley   +1 more source

Development and validation of an eating behavior patient-reported outcome measure in people living with obesity or overweight. [PDF]

Obesity (Silver Spring)
Bushnell DM, Fung S, Brod M, Roberts CA, Le Roux CW, Steen O, Lucas KJ, Hennige AM, Uster A.   +8 more
europepmc   +1 more source

POB10 VALIDATION OF A PATIENT-REPORTED OUTCOMES QUESTIONNAIRE FOR ASSESSING POSITIVE WELL-BEING ASSOCIATED WITH BEHAVIORAL CHANGES

, 2005
X Mesrobian, Polyxane Mertzanis, S Dard
openalex   +1 more source

SensRORing cholesterol to drive protumoral myelopoiesis

Molecular Oncology, EarlyView.
Bleve et al. uncover a cholesterol‐driven immune evasion pathway, where RORγ‐dependent myelopoiesis shapes tumor immunosuppression. Targeting RORγ and PCSK9 emerges as a strategy to boost cancer immunotherapy. Protumoral myelopoiesis is a determinant of immunoevasion and tumor spread in many malignancies.
Sara Gennari, Luigi Nezi, Teresa Manzo
wiley   +1 more source